IS5589A - Kínoxalín notuð sem serínprótínkljúfatálmar, svo sem þáttur xa og þrombín - Google Patents

Kínoxalín notuð sem serínprótínkljúfatálmar, svo sem þáttur xa og þrombín

Info

Publication number
IS5589A
IS5589A IS5589A IS5589A IS5589A IS 5589 A IS5589 A IS 5589A IS 5589 A IS5589 A IS 5589A IS 5589 A IS5589 A IS 5589A IS 5589 A IS5589 A IS 5589A
Authority
IS
Iceland
Prior art keywords
thrombin
factor
protease inhibitors
serine protease
quinoxaline
Prior art date
Application number
IS5589A
Other languages
English (en)
Inventor
Andrea Dudley Danette
John Edmunds Jeremy
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of IS5589A publication Critical patent/IS5589A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS5589A 1998-03-31 2000-08-18 Kínoxalín notuð sem serínprótínkljúfatálmar, svo sem þáttur xa og þrombín IS5589A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8004298P 1998-03-31 1998-03-31
PCT/US1998/026704 WO1999050254A1 (en) 1998-03-31 1998-12-15 Quinoxalinones as serine protease inhibitors such as factor xa and thrombin

Publications (1)

Publication Number Publication Date
IS5589A true IS5589A (is) 2000-08-18

Family

ID=22154891

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5589A IS5589A (is) 1998-03-31 2000-08-18 Kínoxalín notuð sem serínprótínkljúfatálmar, svo sem þáttur xa og þrombín

Country Status (14)

Country Link
US (2) US6410536B1 (is)
EP (1) EP1068190A1 (is)
JP (1) JP2002509923A (is)
KR (1) KR20010042298A (is)
AU (1) AU1917999A (is)
BR (1) BR9815785A (is)
CA (1) CA2319554C (is)
HU (1) HUP0101470A3 (is)
IL (1) IL137655A0 (is)
IS (1) IS5589A (is)
NO (1) NO20004697L (is)
PL (1) PL343321A1 (is)
WO (1) WO1999050254A1 (is)
ZA (1) ZA992447B (is)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
AU3127900A (en) * 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
BR9917036A (pt) * 1999-02-09 2002-07-30 Dimensional Pharm Inc Amidinas heteroarila, metilamidinas e guanidinas como inibidores de protease
SE9902202D0 (sv) * 1999-06-10 1999-06-10 Astra Ab Production of aggregates
EP1255741A2 (en) 2000-02-01 2002-11-13 Cor Therapeutics, Inc. 2- 1H]-QUINOLONE AND 2- 1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
CN101912380A (zh) * 2003-04-15 2010-12-15 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
AU2004249671A1 (en) * 2003-05-20 2004-12-29 Genentech, Inc. Benzofuran inhibitors of factor VIIa
JP2007505160A (ja) * 2003-05-20 2007-03-08 ジェネンテック・インコーポレーテッド 第ＶＩＩａ因子のアシルスルファミド阻害剤
CA2565832A1 (en) * 2004-05-05 2005-11-10 Immunopharm Aktiengesellschaft Preparation for the treatment cancer
DE102004023332A1 (de) * 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2006016278A1 (en) * 2004-08-09 2006-02-16 Warner-Lambert Company Llc Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
WO2006016450A1 (ja) 2004-08-11 2006-02-16 Kowa Company, Ltd. 脳梗塞の予防・治療方法
MX2007004305A (es) * 2004-10-12 2007-06-18 Glenmark Pharmaceuticals Sa Inhibidores novedosos de dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procedimientos para su preparacion.
CA2665476A1 (en) * 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
US7893066B2 (en) 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
CA2681560A1 (en) 2007-04-09 2008-10-16 Cv Therapeutics, Inc. Pteridinone derivatives for use as stearoyl coa desaturase inhibitors
WO2008141081A1 (en) * 2007-05-10 2008-11-20 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
RU2488585C2 (ru) 2007-08-31 2013-07-27 Пэдью Фарма Л.П. Замещенные пиперидиновые соединения хиноксалинового типа и их применение
EA021904B1 (ru) 2008-03-05 2015-09-30 Мерк Патент Гмбх Производные хиноксалинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета
CA2719394A1 (en) * 2008-03-26 2009-10-01 Daiichi Sankyo Company, Limited Hydroxyquinoxalinecarboxamide derivative
WO2009126123A1 (en) * 2008-04-10 2009-10-15 Cv Therapeutics Inc. Bicyclic nitrogen containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
DK2324013T6 (en) 2008-07-21 2014-12-15 Purdue Pharma Lp Substituted bridged piperidine compounds of quinoxalintype and uses thereof
ES2613631T3 (es) 2010-12-22 2017-05-25 Purdue Pharma L.P. Compuestos de piperidina de tipo quinoxalina sustituidos con fósforo y usos de los mismos
WO2013071217A1 (en) 2011-11-10 2013-05-16 OSI Pharmaceuticals, LLC Dihydropteridinones
JP2014533744A (ja) 2011-12-01 2014-12-15 パーデュー、ファーマ、リミテッド、パートナーシップ アゼチジン置換キノキサリンタイプピペリジン化合物とその使用
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
WO2014102588A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
WO2014102592A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
US10517870B2 (en) 2015-07-30 2019-12-31 Bristol-Myers Squibb Company Aryl substituted bicycle heteroaryl compounds
EP3394083B9 (en) 2015-12-24 2022-04-27 The Regents of the University of California N-[5-[(3,4-dimethoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]-2-methoxy-benzeneacetamide derivatives and related compounds as cftr activators for treating constipation or cholestasis
US10604492B2 (en) 2015-12-24 2020-03-31 The Regents Of The Universtiy Of California CFTR regulators and methods of use thereof
EP3394046B1 (en) * 2015-12-24 2022-03-09 The Regents Of The University Of California Cftr regulators and methods of use thereof
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
CN111629730A (zh) 2017-08-24 2020-09-04 加利福尼亚大学董事会 眼部药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082735A (en) 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
US4082736A (en) 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
JPS63145272A (ja) 1986-12-09 1988-06-17 Morishita Seiyaku Kk ４，５−ジヒドロ−６−（４−置換フエニル）−３（２ｈ）−ピリダジノン誘導体
JPS63301874A (ja) * 1987-03-27 1988-12-08 Fujisawa Pharmaceut Co Ltd キノキサリン誘導体およびその製造法
JPH0276860A (ja) * 1987-10-05 1990-03-16 Toyo Jozo Co Ltd ６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体
JPH01254348A (ja) 1988-04-01 1989-10-11 Matsushita Electric Ind Co Ltd 成形用型
HUT76640A (en) 1995-08-17 1997-10-28 Chinoin Gyogyszer Es Vegyeszet Compounds of pharmaceutical activity cyclic amide derivatives, pharmaceutical compositions containing them, process for producing them and their use
AU3232597A (en) * 1996-06-18 1998-01-07 Warner-Lambert Company Pyrrolo{1,2-a}pyrazine-1,4-dione serine protease inhibitors
NZ333696A (en) * 1996-07-08 2000-06-23 Du Pont Pharm Co Amidinoindoles, amidinoazoles, and analogs thereof as inhibitors of trypsin like protease enzymes like thrombin and Xa factor
TW472045B (en) * 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
GB2324729B (en) 1997-04-30 2002-01-02 Bradford Hospitals Nhs Trust Lung treatment device

Also Published As

Publication number Publication date
HUP0101470A2 (hu) 2001-10-28
US6410536B1 (en) 2002-06-25
HUP0101470A3 (en) 2002-09-30
PL343321A1 (en) 2001-08-13
ZA992447B (en) 2000-10-10
IL137655A0 (en) 2001-10-31
AU1917999A (en) 1999-10-18
EP1068190A1 (en) 2001-01-17
CA2319554A1 (en) 1999-10-07
KR20010042298A (ko) 2001-05-25
JP2002509923A (ja) 2002-04-02
US20020086866A1 (en) 2002-07-04
NO20004697D0 (no) 2000-09-20
US6916805B2 (en) 2005-07-12
BR9815785A (pt) 2000-12-05
NO20004697L (no) 2000-09-20
WO1999050254A1 (en) 1999-10-07
CA2319554C (en) 2005-06-28

Similar Documents

Publication Publication Date Title
IS5589A (is) Kínoxalín notuð sem serínprótínkljúfatálmar, svo sem þáttur xa og þrombín
AP2004003035A0 (en) Inhibitors of factor xa and other serine proteasesinvolved in the coagulation cascade.
NO20004698D0 (no) Quinoksalinoner som serin protease inhibitorer sÕ som faktor XA og trombin
IL144032A0 (en) Serine protease inhibitors
NO20012980L (no) Proteaseinhibitorer
EG24589A (en) Carrier with solid fibrinogen and solid thrombin
AU3127900A (en) Thrombin or factor xa inhibitors
EE9800353A (et) Pürasinoonidest trombiini inhibiitorid
NO20011966D0 (no) Serin-protease-inhibitor
IS5553A (is) Kínólón sem serínprótínkljúfatálmar
IL138676A0 (en) Substituted benzamides, their production and their use as cysteine protease inhibitors
ATE264339T1 (de) Serine protease inhibitoren
EP1079835A4 (en) PYRAZINONE AS THROMBINE INHIBITORS
ID16104A (id) Inhibitor-inhibitor serin protease.
DE69714222D1 (de) Serine-protease-inhibitoren
NO20011388L (no) Hydroksamat-inneholdende cystein- og serinproteasehemmere
ZA200005376B (en) Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors.